Mode
Text Size
Log in / Sign up
N/A N=90 Randomized Prevention

Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer

Synchronous Metastasized Breast Cancer · Circulating Tumor Cells

Enrolled (actual)
90
Serious AEs
Results posted
Aug 2024
Primary outcome: Primary: Overall Survival (OS) — 34.6; 56.2 months — p=0.042

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Surgery (Procedure); Surgery on Demand (Procedure)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
Austrian Breast & Colorectal Cancer Study Group
Primary completion
Jul 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Overall Survival (OS)
34.6; 56.2 0.042 sig
SECONDARY
Time to Distant Progression
13.7; 24.4 0.147
SECONDARY
Time to Local Progression (TTPl)
59.4; 55.8 0.890

Summary

Primary Operation in synchronous metastasized invasive breast cancer to evaluate the use of local therapy

Eligibility Criteria

Inclusion Criteria

  • Patients age ≥ 18 years
  • Eastern Cooperative Oncology Group Performance Status is 0 -2
  • Untreated synchronous metastasized invasive carcinoma of the breast with the primary tumor in situ (bilateral synchronous metastasized breast cancer patients are eligible)
  • The primary tumor must be identified and may be any size, however, primary resection with resection free margins must be possible
  • Invasive adenocarcinoma of the breast on histological examination
  • The metastatic site must be identified by radiological assessment(Computer Tomography of the chest and the abdomen OR ultrasound and chest x ray for visceral metastases; bone scan AND/OR computer tomography AND/OR magnetic resonance for bone metastases). A biopsy is not necessary.
  • Written informed consent must be obtained and documented prior to beginning any protocol specific procedures and according to local regulatory requirements
  • able to comply with the protocol requirements during the treatment and follow-up period.

Exclusion Criteria

  • Patients in whom a R0 resection (microscopic free margins) is clinically questionable
  • Inflammatory cancer
  • Patients with a brain metastasis
  • Patients who are not eligible for general anesthesia and operations
  • Patients without metastatic breast cancer (patients with a tumor marker value (CEA, CA15-3) above normal levels without the radiological proven evidence of metastases are not eligible for the study)
  • Patients with a second untreated malignancy
  • Any previous malignancy treated with curative intent and the patient has not been disease-free for 5 years - exceptions are: (a)carcinoma in situ of the cervix, (b)squamous carcinoma of the skin, (c)basal cell carcinoma of the skin
  • Patients with any recurrent cancer disease
  • Pregnant or lactating women
  • Patients are not allowed to be part of another local therapy trial
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01015625). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search